Indoleamine-Pyrrole 2,3,-Dioxygenase
"Indoleamine-Pyrrole 2,3,-Dioxygenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dioxygenase with specificity for the oxidation of the indoleamine ring of TRYPTOPHAN. It is an extrahepatic enzyme that plays a role in metabolism as the first and rate limiting enzyme in the kynurenine pathway of TRYPTOPHAN catabolism.
| Descriptor ID |
D050503
|
| MeSH Number(s) |
D08.811.682.690.416.333
|
| Concept/Terms |
Indoleamine-Pyrrole 2,3,-Dioxygenase- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Indolamine-2,3-Dioxygenase
- Indolamine 2,3 Dioxygenase
- Indoleamine-Oxygen 2,3-Oxidoreductase (Decyclizing)
- IDO Dioxygenase
- Dioxygenase, IDO
- Indoleamine 2,3-Dioxygenase
- Indoleamine 2,3 Dioxygenase
|
Below are MeSH descriptors whose meaning is more general than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
Below are MeSH descriptors whose meaning is more specific than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
This graph shows the total number of publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in this website by year, and whether "Indoleamine-Pyrrole 2,3,-Dioxygenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 2 | 4 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in Profiles.
-
BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Sci Adv. 2024 Jun 21; 10(25):eadj8650.
-
Targeting Lin28 axis enhances glypican-3-CAR T?cell efficacy against hepatic tumor initiating cell population. Mol Ther. 2023 03 01; 31(3):715-728.
-
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. J Transl Med. 2022 11 22; 20(1):541.
-
Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
-
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.
-
Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD. J Am Soc Nephrol. 2021 11; 32(11):2834-2850.
-
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol. 2021 07; 113:20-27.
-
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Front Immunol. 2021; 12:678999.
-
Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021 02; 590(7845):332-337.
-
Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases. Int Rev Immunol. 2022; 41(3):346-363.